Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/56858
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Machado, A. | por |
dc.contributor.author | Martins, J. | por |
dc.contributor.author | Pereira, J. E. | por |
dc.contributor.author | Gama, F. M. | por |
dc.date.accessioned | 2018-11-09T10:46:51Z | - |
dc.date.available | 2018-11-09T10:46:51Z | - |
dc.date.issued | 2018-10-02 | - |
dc.identifier.citation | Machado, A.; Martins, J.; Pereira, J. E.; Gama, F. M., Dextrin: a platform for the development of drug delivery systems. CHEMPOR 2018 - 13th International Chemical and Biological Engineering Conference (Book of Extended Abstracts). No. P-BB20, Aveiro, Portugal, Oct 2-4, 241-242, 2018. | por |
dc.identifier.uri | https://hdl.handle.net/1822/56858 | - |
dc.description.abstract | Dextrin is a biocompatible polysaccharide that can be suited for the conjugation with bioactive agents while enabling controlled release at the target site. LLKKK18, an LL37 human cathelicidin analog, has been engineered to enhance antimicrobial properties and decrease toxicity. In this work, chemically modified dextrin bearing a carboxylic group has been produced to allow the conjugation with LLKKK18 for the treatment of osteomyelitis. FT-IR spectra confirmed dextrin modification while maximum degradability was achieved after approximately 2h. A batch of 30% mol modification was used to conjugate with LLKKK18 and incubated in vitro with Staphylococcus aureus. Conjugates incubated with -amylase were more effective in killing bacteria when compared to conjugates with intact bonds, emphasizing the protective effect of dextrin and indicating a controlled peptide release. | por |
dc.description.sponsorship | The authors acknowledge the funding from FEDER and NORTE 2020 through the project nº 003262 titled “iBONE therapies: advanced solutions for bone regeneration”. This study was supported by Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469 unit and COMPETE 2020 (POCI-01-0145-FEDER-006684) and BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. | por |
dc.language.iso | eng | por |
dc.relation | info:eu-repo/grantAgreement/FCT/5876/147337/PT | por |
dc.rights | openAccess | por |
dc.title | Dextrin: a platform for the development of drug delivery systems | por |
dc.type | conferenceAbstract | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | http://www.chempor2018.com/ | por |
dc.comments | CEB49102 | por |
oaire.citationStartPage | 241 | por |
oaire.citationEndPage | 242 | por |
oaire.citationIssue | P-BB20 | - |
oaire.citationConferencePlace | Aveiro, Portugal | por |
dc.date.updated | 2018-11-09T10:18:51Z | - |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | por |
sdum.conferencePublication | CHEMPOR 2018 - 13th International Chemical and Biological Engineering Conference (Book of Extended Abstracts) | por |
Aparece nas coleções: |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_49102_1.pdf | 535,25 kB | Adobe PDF | Ver/Abrir |